- Home
- MBWM vs ANAB Comparison
MBWM vs ANAB Comparison
Compare MBWM & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBWM
- ANAB
- Stock Information
- Founded
- MBWM 1997
- ANAB 2005
- Country
- MBWM United States
- ANAB United States
- Employees
- MBWM N/A
- ANAB N/A
- Industry
- MBWM Major Banks
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- MBWM Finance
- ANAB Health Care
- Exchange
- MBWM Nasdaq
- ANAB Nasdaq
- Market Cap
- MBWM 709.3M
- ANAB 759.5M
- IPO Year
- MBWM 1997
- ANAB 2017
- Fundamental
- Price
- MBWM $44.12
- ANAB $15.85
- Analyst Decision
- MBWM Buy
- ANAB Buy
- Analyst Count
- MBWM 2
- ANAB 11
- Target Price
- MBWM $54.50
- ANAB $42.67
- AVG Volume (30 Days)
- MBWM 68.0K
- ANAB 635.1K
- Earning Date
- MBWM 01-21-2025
- ANAB 03-10-2025
- Dividend Yield
- MBWM 3.26%
- ANAB N/A
- EPS Growth
- MBWM N/A
- ANAB N/A
- EPS
- MBWM 4.96
- ANAB N/A
- Revenue
- MBWM $222,191,000.00
- ANAB $57,172,000.00
- Revenue This Year
- MBWM N/A
- ANAB $229.13
- Revenue Next Year
- MBWM $0.96
- ANAB N/A
- P/E Ratio
- MBWM $8.91
- ANAB N/A
- Revenue Growth
- MBWM 2.06
- ANAB 282.17
- 52 Week Low
- MBWM $33.46
- ANAB $12.51
- 52 Week High
- MBWM $52.98
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- MBWM 44.65
- ANAB 48.16
- Support Level
- MBWM $43.44
- ANAB $14.76
- Resistance Level
- MBWM $47.59
- ANAB $15.63
- Average True Range (ATR)
- MBWM 1.43
- ANAB 0.99
- MACD
- MBWM 0.14
- ANAB 0.53
- Stochastic Oscillator
- MBWM 50.57
- ANAB 89.66
About MBWM Mercantile Bank Corporation
Mercantile Bank Corp operates as a bank holding company. It provides a variety of commercial banking services to individuals, businesses, governmental units, and other institutions. It provides banking services offering deposit products including checking, savings, and term certificate accounts, and lending products including commercial, residential mortgage, and installment loans. The company generates revenue from interest and dividends earned on loans, securities, and other financial instruments.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).